ReShape Lifesciences Inc.

NASDAQ: RSLS · Real-Time Price · USD
3.92
0.72 (22.50%)
At close: Aug 14, 2025, 3:59 PM

ReShape Lifesciences Cash Flow Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Net Income
-7.13M -11.39M -46.21M -61.93M
Depreciation & Amortization
22K 154K 2.15M 1.97M
Stock-Based Compensation
184K 766K 2.09M 12.23M
Other Working Capital
-11K -337K 770K -608K
Other Non-Cash Items
200K -2.39M 19.79M 34.64M
Deferred Income Tax
6K 28K -423K -60K
Change in Working Capital
2.29M -4.13M 709K -2.74M
Operating Cash Flow
-4.43M -16.96M -21.9M -15.38M
Capital Expenditures
n/a -43K -131K -352K
Cash Acquisitions
n/a n/a 39K 2.21M
Purchase of Investments
n/a n/a -39K n/a
Sales Maturities Of Investments
n/a n/a 639K n/a
Other Investing Acitivies
n/a 33K -600K 2.21M
Investing Cash Flow
n/a -10K -92K 1.85M
Debt Repayment
653K n/a n/a -9.5M
Common Stock Repurchased
n/a n/a n/a n/a
Dividend Paid
n/a n/a n/a n/a
Other Financial Acitivies
24K 17.57M 2.49M 42.8M
Financial Cash Flow
677K 17.57M 3.13M 33.3M
Net Cash Flow
-3.77M 604K -18.86M 19.81M
Free Cash Flow
-4.43M -17M -22.03M -15.73M